Official reprint from UpToDate®
www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 11

of 'Adjuvant therapy for resected stage III (node-positive) colon cancer'

Sargent DJ, Yothers G, Van Cutsem E, et al. Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients frin MOSAIC, X-ACT, PETACC-3, NSABP C06 and C-07, and C89803 (abstract #4011). J Clin Oncol 2009; 27:170s.
no abstract available